Efficacy analysis of CDK4/6 inhibitors (CDKi) plus endocrine therapy (ET) treatment in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (aBC): Biomarker analysis including chemoendocrine score (CES) by CDKi type in SOLTI-1801_CDK-PREDICT study

被引：0
|
作者：
Tolosa Ortega, Pablo
Pascual, Tomas
Hernando, Cristina
Servitja, Sonia
Fernandez-Abad, Maria
Braso-Maristany, Fara
Benitez Fuentes, Javier David
Lema, Laura
Parrilla Rubio, Lucia
Ruano, Yolanda
Maria Roncero, Ana
Sanchez-Bayona, Rodrigo
Alva Bianchi, Manuel
Villacampa, Guillermo
Cobos-Fernandez, Maria Angeles
del Rocio Moreno, Maria
Canes, Jordi
Salvador, Fernando
Prat, Aleix
Ciruelos, Eva M.
机构：
[1] Hosp 12 Octubre, Dept Med Oncol, Madrid, Spain
[2] Hosp Clin Barcelona, August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Dept Med Oncol,SOLTI Breast Canc Cooperat Grp, Barcelona, Spain
[3] Hosp Clin Univ Valencia, Dept Med Oncol, Biomed Res Inst INCLIVA, Valencia, Spain
[4] Hosp Mar, Barcelona, Spain
[5] Ramon y Cajal Univ Hosp, Dept Med Oncol, Madrid, Spain
[6] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain
[7] August Pi & Sunyer Biomed Res Inst IDIBAPS, Barcelona, Spain
[8] Hosp Clin San Carlos, Dept Med Oncol, IdISSC, Madrid, Spain
[9] 12 Octubre Univ Hosp, Madrid, Spain
[10] Hosp Univ 12 Octubre, Dept Pathol, Madrid, Spain
[11] Hosp Univ 12 Octubre Res Inst, Mol Pathol Unit, Madrid, Spain
[12] SOLTI Canc Res Grp, Barcelona, Spain
[13] Univ Hosp 12 Octubre, Dept Med Oncol, Breast Canc Unit, GEICAM Spanish Breast Canc Grp, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1065
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Dissecting the biological activity of different CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
    Lorman-Carbo, Natalia
    Martinez-Saez, Olga
    Fernandez-Martinez, Aranzazu
    Galvan, Patricia
    Chic, Nuria
    Adamo, Barbara
    Vidal, Maria
    Munoz, Montserrat
    Perou, Charles M.
    Gavila, Joaquin
    Pascual, Tomas
    Prat, Aleix
    Braso-Maristany, Fara
    CANCER RESEARCH, 2023, 83 (05)
  • [2] Ribociclib (RIB) plus endocrine therapy (ET) in Japanese women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC)
    Masuda, N.
    Noguchi, S.
    Ishikawa, T.
    Aruga, T.
    Kim, S. J.
    Toyama, T.
    Saeki, T.
    Saito, M.
    Yamanaka, T.
    Watanabe, J.
    Nakamura, S.
    Takahashi, M.
    Inoue, K.
    Gounaris, I.
    Han, Y.
    Samant, T. S.
    Gazdoiu, M.
    Ito, Y.
    ANNALS OF ONCOLOGY, 2018, 29
  • [3] CDK4/6 inhibition and endocrine therapy (ET) in the HER2-enriched subtype (HER2-E) in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (ABC): A retrospective analysis of real-world data
    Martinez-Saez, O.
    Tolosa, P.
    Sanchez De Torre, A.
    Pascual, T.
    Braso-Maristany, F.
    Rodriguez Hernandez, A.
    Parrilla, L.
    Roncero, A. M.
    Ruano, Y.
    Chic, N.
    Schettini, F.
    Laguna, J. C.
    Sanfeliu Torres, E.
    Gonzalez-Farre, B.
    Vidal, M.
    Adamo, B.
    Guillen Sacoto, M. C.
    Munoz, M.
    Prat, A.
    Ciruelos, E. M.
    ANNALS OF ONCOLOGY, 2021, 32 : S30 - S30
  • [4] Efficacy analysis of CDK4/6 inhibitors in combination with endocrine therapy treatment in HR+/HER2-breast cancer according to PAM50 intrinsic subtype: primary results of SOLTI-1801_CDK-PREDICT study
    Tolosa, Pablo
    Pascual, Tomas
    Hernando, Cristina
    Servitja, Sonia
    Fernandez, Adela
    Braso-Maristany, Fara
    Benitez, Javier
    Lema, Laura
    Ruano, Yolanda
    Parrilla, Lucia
    Roncero, Ana Maria
    Sanchez-Bayona, Rodrigo
    Alva, Manuel
    Villacampa, Guillermo
    Moreno-Villa, Maria Rocio
    Canes, Jordi
    Salvador, Fernando
    Prat, Aleix
    Ciruelos, Eva
    CANCER RESEARCH, 2023, 83 (05)
  • [5] Biomarker analyses of Asian women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) receiving ribociclib (RIB) plus endocrine therapy (ET)
    Yap, Y. S.
    Masuda, N.
    Ito, Y.
    Ishikawa, T.
    Kim, S. J.
    Aruga, T.
    Toyama, T.
    Saeki, T.
    Yamanaka, T.
    Saito, M.
    Watanabe, J.
    Takahashi, M.
    Nakamura, S.
    Inoue, K.
    Suarez-Vizcarra, J.
    He, W.
    Solovieff, N.
    Su, F.
    Chiu, J.
    ANNALS OF ONCOLOGY, 2018, 29 : 13 - +
  • [6] Subsequent therapies after progressing to CDK4/6 inhibition (CDK4/6i) in hormone receptor positive/HER2 negative (HR+/HER2-) advanced breast cancer (ABC)
    Laguna, J. C.
    Braso-Maristany, F.
    Pascual, T.
    Rodriguez Hernandez, A.
    Chic, N.
    Schettini, F.
    Sanfeliu Torres, E.
    Gonzalez-Farre, B.
    Martinez, D.
    Galvan, P.
    Diez-Guardia, V.
    Adamo, B.
    Vidal, M.
    Guillen Sacoto, M. C.
    Moreno, R.
    Prat, A.
    Munoz, M.
    Martinez-Saez, O.
    ANNALS OF ONCOLOGY, 2021, 32 : S69 - S70
  • [7] Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor-Positive (HR+)/HER2-Negative Metastatic Breast Cancer
    Davis, Andrew A.
    Luo, Jingqin
    Zheng, Tiantian
    Dai, Chao
    Dong, Xiaoxi
    Tan, Lu
    Suresh, Rama
    Ademuyiwa, Foluso O.
    Rigden, Caron
    Rearden, Timothy P.
    Clifton, Katherine
    Weilbaecher, Katherine
    Frith, Ashley
    Tandra, Pavan K.
    Summa, Tracy
    Haas, Brittney
    Thomas, Shana
    Hernandez-Aya, Leonel F.
    Peterson, Lindsay L.
    Wang, Xiaohong
    Luo, Shujun J.
    Zhou, Kemin
    Du, Pan
    Jia, Shidong
    King, Bonnie L.
    Krishnamurthy, Jairam
    Ma, Cynthia X.
    CLINICAL CANCER RESEARCH, 2023, 29 (09) : 1719 - 1729
  • [8] Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT study
    Tolosa, Pablo
    Pascual, Tomas
    Martinez-Saez, Olga
    Hernando, Cristina
    Servitja, Sonia
    Abad, Maria Fernandez
    Braso-Maristany, Fara
    Sanfeliu, Ester
    Fuentes, Javier David Benitez
    Lema, Laura
    Ruano, Yolanda
    Garcia-Fructuoso, Isabel
    Parrilla, Lucia
    Rodriguez, Adela
    Roncero, Ana Maria
    Cobos, Maria Angeles
    Sanchez-Bayona, Rodrigo
    Alva, Manuel
    Madariaga, Ainhoa
    Villacampa, Guillermo
    Canes, Jordi
    Salvador, Fernando
    Sanchez-Belmonte, Agustin
    Malumbres, Marcos
    Prat, Aleix
    Ciruelos, Eva
    EUROPEAN JOURNAL OF CANCER, 2025, 217
  • [9] CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
    Matutino, Adriana
    Amaro, Carla
    Verma, Sunil
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [10] CDK4/6-Inhibitors Inclusion in the Treatment of metastatic Hormone Receptor-positive, HER2-negative Breast Cancer
    Forstmeyer, D.
    ONKOLOGE, 2016, 22 (07): : 507 - 508
12345